Cancer immunotherapy using a polysaccharide from Codium fragile in a murine model.

Hae-Bin ParkSeong-Min LimJuyoung HwangWei ZhangSangGuan YouJun-O Jin

Published in: Oncoimmunology (2020)

CFP: Codium fragile polysaccharide; NK: natural killer; IFN: interferon; TNF: tumor necrosis factor; IL: interleukin; tdLN: tumor draining lymph node; BMDC: bone marrow-derived dendritic cell; OVA: ovalbumin; Ab: antibody; Ag: antigen; DC: dendritic cell; CTL: cytotoxic T lymphocyte; APC: antigen-presenting cell; pDC: plasmacytoid dendritic cell; mDC: myeloid dendritic cell; MHC: major histocompatibility complex; CR3: complement receptor type 3; TLR: Toll-like receptor; LPS: lipopolysaccharide; SP: sulfated polysaccharide; TRP2: tyrosinase-related protein 2; SR-A: scavenger receptor-A.

Keyphrases

dendritic cells
toll like receptor
immune response
inflammatory response
lymph node
nuclear factor
regulatory t cells
rheumatoid arthritis
lps induced
cell therapy
neoadjuvant chemotherapy
squamous cell carcinoma
binding protein
acute myeloid leukemia
water soluble
locally advanced